RxDoctor Payments DataLook up a doctor →

Richard Sadowitz, MD

Gastroenterology · Chattanooga, TNNPI 1639175631

Payments from drug & device makers

$128,390in general payments, 2019–2025

Across 756 payments — averaging $169.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Immunogenx, Inc.$86K
  • AstraZeneca$14K
  • Amgen$12K
  • AbbVie$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Johnson & Johnson$1K
  • plus $6K from 28 others

What the payments were for

  • Speaking & faculty fees$2001%
  • Food & beverage$15,74598%
  • Education$1071%
  • Gifts$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,390 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$56,058
Medicare patients
269
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide416$272,909
CreonLipase/Protease/Amylase59$224,700
ZenpepLipase/Protease/Amylase28$188,203
XifaxanRifaximin48$171,372
Dexlansoprazole DrDexlansoprazole154$38,965
Alosetron Hcl25$16,922
Sucralfate270$14,655
Budesonide ErBudesonide15$14,256
Pantoprazole Sodium775$11,532
Esomeprazole Magnesium230$10,892
SutabSod Sulf/Pot Chloride/Mag Sulf56$8,709
Famotidine458$7,301
Lubiprostone39$6,137
Dicyclomine Hcl183$5,222
Mesalamine32$4,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$5,945$497,609475 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,128$171,37248 claims
Braintree Laboratories, Inc.Sutab$180$8,70956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →